ACRS
Income statement / Annual
Last year (2024), Aclaris Therapeutics, Inc.'s total revenue was $18.72 M,
a decrease of 40.09% from the previous year.
In 2024, Aclaris Therapeutics, Inc.'s net income was -$132.07 M.
See Aclaris Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$18.72 M |
$31.25 M |
$29.75 M |
$6.76 M |
$6.48 M |
$4.23 M |
$10.09 M |
$1.68 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.79 M
|
$18.08 M
|
$11.96 M
|
$4.71 M
|
$5.13 M
|
$4.06 M
|
$6.85 M
|
$1.21 M
|
$120,000.00
|
$90,000.00
|
| Gross Profit |
$15.93 M
|
$13.17 M
|
$17.79 M
|
$2.05 M
|
$1.35 M
|
$172,000.00
|
$3.24 M
|
$476,000.00
|
-$120,000.00
|
-$90,000.00
|
| Gross Profit Ratio |
0.85
|
0.42
|
0.6
|
0.3
|
0.21
|
0.04
|
0.32
|
0.28
|
0
|
0
|
| Research and Development Expenses |
$33.59 M
|
$98.38 M
|
$77.81 M
|
$43.81 M
|
$31.73 M
|
$64.90 M
|
$63.01 M
|
$39.79 M
|
$33.48 M
|
$15.34 M
|
| General & Administrative Expenses |
$22.20 M
|
$31.10 M
|
$25.13 M
|
$23.62 M
|
$20.53 M
|
$27.16 M
|
$27.65 M
|
$33.11 M
|
$15.09 M
|
$5.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$283,000.00
|
$671,000.00
|
$48.00 M
|
$85,000.00
|
$3.30 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.20 M
|
$31.10 M
|
$25.13 M
|
$23.62 M
|
$20.53 M
|
$27.83 M
|
$75.65 M
|
$33.11 M
|
$15.09 M
|
$5.33 M
|
| Other Expenses |
$102.07 M
|
-$18.96 M
|
$2.95 M
|
-$1.14 M
|
-$424,000.00
|
-$2.48 M
|
$2.68 M
|
$2.07 M
|
$488,000.00
|
$0.00
|
| Operating Expenses |
$157.86 M
|
$110.53 M
|
$102.95 M
|
$67.43 M
|
$52.26 M
|
$92.73 M
|
$138.66 M
|
$72.90 M
|
$48.57 M
|
$20.67 M
|
| Cost And Expenses |
$160.65 M
|
$128.61 M
|
$114.91 M
|
$72.15 M
|
$57.39 M
|
$96.78 M
|
$145.51 M
|
$74.11 M
|
$48.57 M
|
$20.67 M
|
| Interest Income |
$7.95 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$104,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$4.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$807,000.00
|
$863,000.00
|
$797,000.00
|
$923,000.00
|
$1.32 M
|
$1.59 M
|
$1.32 M
|
$402,000.00
|
$120,000.00
|
$90,000.00
|
| EBITDA |
-$51.72 M |
-$117.57 M |
-$84.36 M |
-$65.06 M |
-$48.20 M |
-$90.84 M |
-$80.78 M |
-$53.45 M |
-$48.57 M |
-$20.67 M |
| EBITDA Ratio |
-2.76
|
-3.76
|
-2.84
|
-9.62
|
-7.44
|
-21.49
|
-8.01
|
-31.76
|
0
|
0
|
| Operating Income Ratio |
-7.58
|
-3.12
|
-2.86
|
-9.67
|
-7.85
|
-26.27
|
-13.42
|
-43.03
|
0
|
0
|
| Total Other Income/Expenses Net |
$9.87 M
|
$8.51 M
|
$2.95 M
|
-$1.14 M
|
-$424,000.00
|
-$2.48 M
|
$2.68 M
|
-$15.99 M
|
$488,000.00
|
$104,000.00
|
| Income Before Tax |
-$132.07 M
|
-$88.85 M
|
-$86.91 M
|
-$90.87 M
|
-$51.34 M
|
-$113.54 M
|
-$132.74 M
|
-$70.35 M
|
-$48.08 M
|
-$20.56 M
|
| Income Before Tax Ratio |
-7.05
|
-2.84
|
-2.92
|
-13.44
|
-7.92
|
-26.86
|
-13.15
|
-41.8
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$367,000.00
|
$1.75 M
|
$23.42 M
|
-$182,000.00
|
$29.31 M
|
$2.68 M
|
-$1.83 M
|
-$120,000.00
|
-$90,000.00
|
| Net Income |
-$132.07 M
|
-$88.48 M
|
-$88.66 M
|
-$114.28 M
|
-$51.15 M
|
-$142.85 M
|
-$132.74 M
|
-$68.52 M
|
-$48.08 M
|
-$20.56 M
|
| Net Income Ratio |
-7.05
|
-2.83
|
-2.98
|
-16.9
|
-7.89
|
-33.79
|
-13.15
|
-40.71
|
0
|
0
|
| EPS |
-1.71 |
-1.27 |
-1.36 |
-2.01 |
-1.2 |
-3.46 |
-4.03 |
-2.44 |
-2.25 |
-3.37 |
| EPS Diluted |
-1.71 |
-1.27 |
-1.36 |
-2.01 |
-1.2 |
-3.46 |
-4.03 |
-2.44 |
-2.25 |
-3.37 |
| Weighted Average Shares Out |
$77.30 M
|
$69.81 M
|
$65.21 M
|
$56.73 M
|
$42.54 M
|
$41.32 M
|
$32.91 M
|
$28.10 M
|
$21.42 M
|
$6.11 M
|
| Weighted Average Shares Out Diluted |
$77.30 M
|
$69.81 M
|
$65.21 M
|
$56.73 M
|
$42.54 M
|
$41.32 M
|
$32.91 M
|
$28.10 M
|
$21.42 M
|
$6.11 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
